Semaglutide 7 mg and 14 mg tablets are now available for reducing the risk of cardiovascular death, heart attack, or stroke ...

Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its ...

Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...

Novo Nordisk (NVO) stock is in focus as the FDA OKs a label revison for the company's GLP-1 pill Rybelsus to cut ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

Discover how FTIR spectroscopy enhances quality control in GLP-1 weight loss drug production by ensuring molecular ...

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by ...